<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111436</url>
  </required_header>
  <id_info>
    <org_study_id>20030115</org_study_id>
    <nct_id>NCT00111436</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects</brief_title>
  <official_title>An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of long-term
      administration of etanercept in adults with psoriasis who have participated in previous
      etanercept psoriasis studies. This study will also evaluate the maintenance of the efficacy
      of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis
      studies. All subjects enrolled in this study will receive 50 mg once weekly or twice weekly
      (if qualified after week 12) by subcutaneous injections for at least 48 weeks and up to 72
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of adverse events, including infectious episodes</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory values</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psoriasis Area and Severity Index (PASI) Score in this study relative to baseline in the original study</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve 0 or 1 (clear or almost clear) in the Physician Global Assessment of psoriasis</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of psoriasis</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent improvement from baseline in the Dermatology Life Quality Index (DLQI) scores</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in SF-36 Health Survey scores</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">912</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Enbrel 50 mg once weekly or 50 mg twice weekly</description>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_label>50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Subjects who were randomized and received at least one dose of investigational product in
        Study 20021639 or 20021642 (provided that they meet all inclusion/exclusion criteria of
        this protocol)

        Exclusion Criteria:

          -  Active guttate, erythrodermic, or pustular psoriasis at the time of the screening
             visit

          -  Pregnant or breast-feeding females

          -  Evidence of skin conditions at the time of the screening visit (e.g., eczema) that
             would interfere with evaluations of the effect of the investigational product on
             psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.enbrel.com/index.jsp?f=7</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007 Jan;156(1):138-42.</citation>
    <PMID>17199580</PMID>
  </results_reference>
  <results_reference>
    <citation>Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010 Aug;9(8):928-37.</citation>
    <PMID>20684143</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2005</study_first_submitted>
  <study_first_submitted_qc>May 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2005</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis, adults, skin</keyword>
  <keyword>Phase 3, clinical trial</keyword>
  <keyword>Amgen, etanercept</keyword>
  <keyword>EnbrelÂ®, moderate</keyword>
  <keyword>severe, extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

